Clive Dix, chief executive of C4X Discovery Holdings PLC (AIM:C4XD) talks investors through performance in the year to July.
He says the firm is now in a good position for advancement and expansion in the current year.
The drug discovery company reported revenue of £5.6mln in the year to 31 July 2021, after it received a €7mln upfront payment from Sanofi on the signing of the licence agreement for C4XD’s oral inhibitor programme IL-17A to treat psoriasis, which is worth up to €414mln.